The world’s largest manufacturer of Metal Injection Molding components hits the market with a ~Rs 3,812 crore issue
Indo-MIM Ltd., the global leader in precision engineering components manufactured using Metal Injection Molding technology, opens for subscription on July 23 with the issue closing on July 27. With over 25 years of experience, the company holds a 6.8% share of the global MIM market by revenue in CY2025 and has held this leadership position for six consecutive years.
The issue is a combination of a fresh issue of Rs 500 crore and a large Offer for Sale of Rs 3,312 crore — with the latter providing an exit to existing stakeholders.
What the Company Does
Indo-MIM provides end-to-end solutions for precision engineering components, covering mold designing and tooling, component manufacturing, finishing, and assembly. Beyond its core MIM capability, the company also employs investment casting, precision machining, ceramic injection molding, and metal 3D printing — giving it a diversified manufacturing technology platform. Its product portfolio spans automotive, defence, medical, consumer, and aerospace sectors, with over 9,000 types of products manufactured in FY26.
The company operates 15 manufacturing facilities globally — six in India, six in the United States, two in the UK, and one in Mexico. This dual-shore model allows it to serve both Indian and global OEMs while offering supply chain security and domestic manufacturing capability where required. It has 608 tool developments to its credit as of March 31, 2026, serving more than 1,100 customers globally, with a dedicated sales presence in China, Germany, and the USA and representatives across Europe and Asia.
Its facilities carry internationally recognised certifications including NADCAP, IATF 16949, AS 9100, ISO 13485, and ISO 45001. As of March 31, 2026, it had 4,424 employees and an additional 2,766 contract labourers.
Issue Details
| Particulars | Details |
|---|---|
| Issue Opens | July 23, 2026 |
| Issue Closes | July 27, 2026 |
| Listing Date | July 30, 2026 (BSE & NSE) |
| Price Band | Rs 461 – Rs 485 per share |
| Face Value | Re 1 |
| Total Issue Size | ~Rs 3,812 crore (at upper cap) |
| Fresh Issue | Rs 500 crore |
| Offer for Sale | Rs 3,312 crore |
| Total Shares | 7,86,00,300 shares |
| Minimum Lot | 30 shares |
| Employee Discount | Rs 45 per share |
| Post-Issue Market Cap | Rs 23,981.42 crore (at upper cap) |
| Issue Constitutes | 15.90% of post-IPO equity |
| QIB / NII / Retail Split | Up to 75% / at least 15% / at least 35% |
| BRLMs | HDFC Bank, Axis Capital, ICICI Securities, Kotak Mahindra Capital, SBI Capital Markets |
| Registrar | MUFG Intime India Pvt. Ltd. |
Post-IPO, paid-up equity capital will increase from Rs 48.42 crore to Rs 49.45 crore. The company also raised Rs 1,141 crore from 92 anchor investors at Rs 485 per share ahead of the IPO opening.
Objects of the Issue
From the fresh issue proceeds, Rs 400 crore will go towards repayment or prepayment of certain borrowings, with the balance for general corporate purposes. No proceeds are received by the company from the OFS portion.
Financial Performance
| Particulars (Rs cr) | FY24 | FY25 | FY26 |
|---|---|---|---|
| Total Income | 2,900.38 | 3,373.97 | 4,320.70 |
| Net Profit | 283.73 | 423.73 | 533.54 |
| PAT Margin | 9.88% | 12.73% | 12.72% |
| RoCE | 19.59% | 23.51% | 26.60% |
Revenue and profit have grown consistently across all three reported periods, with PAT margins holding steady around 12–13% in FY25 and FY26 and RoCE improving each year to reach 26.60% in FY26. The three-year average EPS stands at Rs 9.44 and average RoNW at 19.61%. The company has also maintained a strong dividend track record, paying 775% in FY24 and 591% in FY25. One note of caution: consolidated contingent liabilities of Rs 227.45 crore as of March 31, 2026 are meaningful, and higher trade receivables are flagged as a concern by analysts.
Valuation and Peer Comparison
At the upper band of Rs 485, the issue is valued at a P/E of 44.95x on FY26 earnings and 56.59x on FY25 earnings, and at a P/BV of 7.22x on post-IPO NAV of Rs 67.13. Independent analysts describe the issue as aggressively priced. The company has no listed Indian peers — the only disclosed comparable is Jiangsu Glan Technology Co. Ltd., a global listed player, which reportedly trades at around 148x P/E — a reference point that makes the Indo-MIM valuation look relatively more reasonable in a global context, even if the comparison is imperfect.
The GMP in the grey market currently stands at around Rs 155–185 per share, indicating an estimated listing premium of roughly 32–38% over the upper price band of Rs 485, with an estimated listing price in the range of Rs 640–670 per share — making it one of the most closely watched IPOs of this primary market season.
Risks to Consider
The issue is overwhelmingly an OFS — Rs 3,312 crore of the Rs 3,812 crore total goes to selling shareholders — meaning a large portion of proceeds exits with existing investors rather than being deployed into the business. At a market cap of nearly Rs 24,000 crore, the valuation is demanding and leaves limited room for near-term disappointment. Contingent liabilities of Rs 227.45 crore and elevated trade receivables are structural balance-sheet risks worth monitoring.
The MIM business requires continuous investment in mold development and tooling — 608 tools developed is a major asset, but maintaining this pipeline demands sustained R&D and capex. Customer concentration may also be a factor given the B2B, repeat-order nature of the industry.